A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed State

Clinical Drug Investigation · Published 2026-02-07 · DOI 10.1007/s40261-026-01528-0

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s40261-026-01528-0

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles